Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting tags : Positive save search
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Published: 2024-04-18 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.36 -10.53% 96K
|
|
| O: -0.63%
H: 1.89%
C: -4.4%
neurology presentation readout positive topline meeting
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 22K
|
Health Technology
|
| O: 2.36%
H: 6.6%
C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% 22K
|
Health Technology
|
| O: 3.2%
H: 0.0%
C: -0.28%
qn-302 association positive cancer research meeting therapeutics
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
GALT | $3.25 -3.85% 120K
|
Health Technology
|
| O: 2.19%
H: 6.15%
C: 5.35%
metabolic positive for meeting hypertension therapeutics study
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
VINC | $0.8747 -2.81% 230K
|
|
| O: -65.69%
H: 0.84%
C: -35.37%
vip236 pharma association positive cancer pipeline research for meeting
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | $11.79 0.09% 43K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Published: 2024-04-06 (Crawled : 16:20) - globenewswire.com
OCUL | News | $5.165 -11.86% 5.1M
|
Health Technology
| Email alert
Add to watchlist
glaucoma ocular positive meeting
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Published: 2024-03-25 (Crawled : 13:30) - biospace.com/
IONS | $40.465 -0.85% 260K
|
Health Technology
|
| O: -0.14%
H: 3.12%
C: 2.93%
positive meeting cardiology
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | News | $0.3669 -0.81% 1.2M
|
n/a
|
| O: 7.14%
H: 5.53%
C: -4.67%
cyb003 fda positive meeting program design
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
NVNO | $4.73 -1.05% 35K
|
Manufacturing
|
| O: 2.96%
H: 3.48%
C: -9.7%
enous2024 positive topline meeting trial today
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - hancockjaffe.com
NVNO | $4.73 -1.05% 35K
|
Manufacturing
|
| O: 2.96%
H: 3.48%
C: -9.7%
enous2024 venovalve positive topline meeting trial today
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-03-06 (Crawled : 13:30) - prnewswire.com
GNPX | $2.2194 22K
|
Health Technology
|
| O: 24.27%
H: 5.66%
C: -14.45%
reqorsa lung positive treatment system preclinical meeting therapy
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Published: 2024-02-22 (Crawled : 12:00) - globenewswire.com
PHVS | $18.19 -1.25% 110K
|
|
| O: -0.22%
H: 3.95%
C: 0.11%
deucrictibant positive treatment meeting results study
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
Published: 2024-02-05 (Crawled : 14:00) - globenewswire.com
SPRY S | $8.4 -0.47% 260K
|
Manufacturing
|
| O: 0.16%
H: 2.2%
C: 0.16%
neffy positive pharmaceuticals meeting
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
Published: 2024-01-31 (Crawled : 15:00) - biospace.com/
ENSC | $0.5301 -8.64% 150K
|
Health Technology
|
| O: 29.51%
H: 4.55%
C: -13.14%
pf614 fda positive treat meeting
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
DARE | $0.2825 -4.27% 390K
|
Health Technology
|
| O: -2.16%
H: 8.61%
C: 1.06%
fda company positive bioscience meeting
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Published: 2024-01-23 (Crawled : 17:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
genetic association positive research meeting trial therapy
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
Published: 2023-12-18 (Crawled : 23:00) - biospace.com/
CYTH | $1.15 -4.17% 25K
|
Professional, Scientific, and T...
|
| O: 8.03%
H: 0.54%
C: -6.76%
trappsol fda disease positive treatment meeting program therapeutics
Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
Published: 2023-12-12 (Crawled : 17:00) - prnewswire.com
SNDX | $20.77 1.37% 280K
|
Health Technology
|
| O: -0.56%
H: 1.57%
C: -0.95%
gment-101 presentation positive meeting leukemia trial
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
Published: 2023-12-12 (Crawled : 07:00) - biospace.com/
VRTX | News | $395.0 0.39% 550K
|
Health Technology
|
| O: 1.04%
H: 0.5%
C: -0.63%
positive trials meeting results
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.